Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BI 765179 + Ezabenlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 765179 | BI765179|BI-765179 | TNFRSF9 Antibody 27 | BI 765179 is a bispecific antibody that targets TNFRSF9 (CD137; 4-1BB) expressed on immune cells and fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts, which potentially results in activation of immune cells and a T-lymphocyte mediated immune response against tumor cells (NCI Drug Dictionary). | |
Ezabenlimab | BI754091|BI-754091|BI 754091 | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112 | Ezabenlimab (BI 754091) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) | Recruiting | USA | ITA | ESP | BEL | 2 |